Celecoxib for arthritis
Article Abstract:
The FDA has approved the drug celecoxib for the treatment of arthritis. Marketed under the name Celebrex, the drug inhibits the enzyme cyclooxygenase-2 (COX-2). COX-2 is found in the joint fluid of people with rheumatoid arthritis. Celebrex inhibits COX-2 but not COX-1. Clinical trials have found Celebrex to be as effective as naproxen in the treatment of rheumatoid arthritis. It has some of the adverse effects of other non-steroidal anti-inflammatory drugs but is less likely to cause ulcers.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
Topotecan hydrochloride for metastatic ovarian cancer
Article Abstract:
Intravenous topotecan (Hycamtin) may be a somewhat effective palliative drug for advanced ovarian cancer not responsive to other chemotherapy. Modest benefits were seen in patients receiving topotecan but some toxic side effects occurred. The most common reactions were anemia and reductions in the level of blood platelets and white blood cells called neutrophils. A single five-day supply costs $2,437.50. It is not clear if topotecan can be used in combination with other drugs.
Publication Name: Medical Letter on Drugs and Therapeutics
Subject: Health
ISSN: 0025-732X
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Problems in diagnosis and management of desmoid tumors. Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors
- Abstracts: Progestogens, lipid metabolism and hormone replacement therapy
- Abstracts: Audit from preschool developmental surveillance of vision, hearing, and language referrals